Yes, vey true. I too do not expect any BT status grant to the MF trial before enough progress is made in Ph 2; but, with Janssen now doing all of it, it should be attained much faster than had Geron be doing it. Tefferi's involvement must have this precondition OR Janssen wanted Tefferi on the team. Whatever it is, I think, IMET is now in the right hands and, if Geron board is wise to look for its shareholders interest, the change is better for us.
Do not forget that Geron still owns a lot of patents and did develop IMET, the BTD drug that brought history's first CRs and PRs for those dying cancer patients. Its Further development looks bright. Yes, those shareholders who held the shares since 90s have been frustrated and rightly so. But, that can't be true for those who became shareholders just a few years back. If those early holders keep their shares for a few more years, it may not be so bad. I think the company had IMET up its sleeve and decided to concentrate on it which resulted in expulsion of Okarma and bringing in Scarlett. Now that Scarlett's job is pretty much done, he will be given a decent severance package and let go. Stay tuned! My views, of course!!
You may not be able to double so soon because it will take time for institutional investors to see the light at the other end!! These guys may be still waiting to see what comes out of Ph 2 MF trial and weigh its benefits. Yes, you will have to be patient with Geron shares in your portfolio. My view, of course!!
Smiggy, you are wrong to judge such a company based on its past as you perceive it!! This is not a Sears or a Walmart!! I went into it a few years back and can see positive changes since then, although, I felt some times that the company had taken wrong steps, especially when it sold of the stem-cell assets cheap. Now, I see that they knew they had a gem in their hand which they wanted to concentrate on. I think it's been headed in the right direction now. If you do not like what you see, of course, step out to look for greener pastures elsewhere; but, sincerely, I am staying in!!
They did develop a BTD drug that brings about for the first time in the history CRs and PRs to dying cancer patients!! Not a small achievement!!! They may have a next one up their sleeve!!
Black, Geron must have something up its sleeve in terms of at least one exciting new product and Janssen will take advantage of its clinical-stage small-outfit organization to develop it to trial stage. I do not think a merger is in the wings soon!! For a company like J&J a few hundred million dollars saving you are talking about is out of consideration in view of a much bigger prize later!! Just do not dream about it!!! Be patient and watch what comes later. Scarlett may be out soon (because his million dollar plus is too much to oversee pure research work and a staff of only 21. The board will have to squeeze him out.
in my view, are apparent from the statements made by Scarlett to-day during the CC. Originally, we were told that the MF trial IND was transferred from Mayo to Geron; now, it is going to Janssen and, hence, Geron doesn't need to add to its staff and will shrink it down to 21. This change is a bit more time-consuming and, hence, the MF trial delay. Thus, Geron is practically out of the trial and Tefferi will be working with far-better hands than at Geron and the trial, once begun, will move much faster and more efficiently as Janssen is well-liked by the FDA. Geron, on the other hand, is to concentrate on further research for NEW products in the field of oncology (primarily in hematological applications but may go beyond) as Janssen takes over the MF/MDS trials and also work related to further applications of IMET. In simple words, IMET is being sold to Janssen and, if Geron succeeds in developing exciting new products (very likely in my view), Janssen may grab those too to develop those as commercial products!! In my view, thus, the stage is set for eventual merger with Janssen, meaning, down the road, we Geron shareholders will become J&J shareholders!!
All in all, I am excited with these developments because IMET is now in good hands and Scarlett may be shown the door out by the board (his job is done!!) to get someone more acceptable to Janssen and who is more apt for further research. (Would that Russian doctor who developed IMET be brought back?) Perhaps a right guy from Janssen may be the best candidate to replace Scarlett!!
I think this is best for the shareholders who want to hold the shares for a long-term investment. Of course, mon...key traders will be mad (who were looking for quick profits) and will selloff to-morrow! Shorts, primarily the hedge funds, will exit too, gradually. Buying opportunities for long-term investors are being created. -Huh may have to quit Any thoughts? Only serious responses, please!
Center, this board is flushed with vermin traders. Despite optimism expressed by Wotton, there will be vermin attack!! These are guys who were hoping for a partnership deal announced TO-DAY so that they can make some bucks. With no such deal, they are forced to be losers and will vent their frustration. Unfortunately, these vermin have flocked heavily in the market in search of easy money!!
Mon...keys can't digest significant news!! They are blind with their greed to make a quick buck. It's better they get out of Ocat so it has its ownership in better hands.
If you tread the post it wasn't pumping; it was a comparison!! Just read posts carefully. By the way, Exel has been going up now and has doubled!! Can you guess why?
is that mon...keys rushed to buy the shares and jacked up the SP like crazy assuming that the Nasdaq listing will be followed by heavy rush from institutional investors; but, having found no such thing, began exiting empty handed to find other greener pastures. Idiots do not know that institutional investors do not get into such biotechs until they see Ph 3 OR if an FTD is granted during Ph 2 or a merger or good partnership deal goes through. None of that happened yet. Well... they have peanut-size brain and can't comprehend any sophistication. They want quick buck and flock like bees where there is an action. This greed or habit gets them frustrated often; but, mon...keys are mon....keys!!
has become a boring board consisting of stereotype, propagandist or agenda-full and lies-full posts. Perhaps that's what Yahoo wants to sell its advertisements. Posts with something meaningful or insightful is getting rare and rare. So, let it be used by vermin who need it to pass their time and post their lies.
If so, vermin should be in the outer space, not on the earth!! There they can multiply as much as they want without being significant; but, this board then will be free of the insects and will be more meaningful!!!
I think it's time now that there must be some news w.r.t. the multi-center trial setup and start. Scarlett may announce expected start date for the trial and other relevant details.
Do not forget that Tefferi WAS retained and the deal with J&J WAS made by the management!! It showed foresight in doing so; but, not effective in doing things themselves (like they screwed up the ET/PV trials and handling other things in the past and yet squeezed hefty salaries and bonuses) !!